MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Health Care Conference.
TD Cowen's 45th Annual Health Care Conference is taking place on March 3-5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the Health Care industry.
TD Cowen | Boston, MA | March 3-5, 2025
Presentation: Tuesday, March 4, 2025 at 11:10 AM ET
Webcast: Click here to access
Institutional investors interested in meeting with senior management may contact their TD Cowen representative.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website or through the conference site by using the link above. A replay will be available on the Company’s website following the event.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.69 |
Daily Change: | 0.06 0.90 |
Daily Volume: | 478,027 |
Market Cap: | US$989.850M |
October 06, 2025 July 30, 2025 May 05, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load